ABOUT JNBH

The Journal of Medical Genetics and Genomics (JNBH) is published monthly (one volume per year) by Academic Journals.

Journal of Medical Genetics and Genomics (JNBH) is an open access journal that provides rapid publication (monthly) of articles in all areas of the subject such as metagenics, evolutionary anthropology, fragile X syndrome, immunotherapy etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in JNBH are peer reviewed.

Submission of Manuscript

Submit manuscripts as e-mail attachment to the Editorial Office at: jnbh@academicjournals.org. A manuscript number will be mailed to the corresponding author shortly after submission.

The Journal of Medical Genetics and Genomics will only accept manuscripts submitted as e-mail attachments.

Please read the Instructions for Authors before submitting your manuscript. The manuscript files should be given the last name of the first author.
Editors

Prof. Viroj Wiwanitkit, M.D.
Wiwanitkit House, Bangkhae,
Bangkok Thailand 10160.
Visiting Prof. Tropical Medicine,
Hainan Medical College,
Hainan China.

Dr. Israel Fernandez-Cadenas
Neurovascular Research Laboratory,
Institut de Recerca, Vall d’Hebron Hospital,
Barcelona.
Spain

Dr. Wani H Ibrahim
Qualifications: FRCP (Edin), FRCP (Glasg), FCCP
Hamad General Hospital, Weill-Cornell Medical
College
Qatar

Prof. Kenneth Blum
Institution Department of Psychiatry,
University of Florida college of Medicine,
Gainesville, Fl
USA

Dr. Abd El-Latif Hesham
Genetics Department, Faculty of Agriculture,
Assiut University
Egypt

Prof. Viroj Wiwanitkit
Wiwanitkit house, bangkhae, Bangkok Thailand
10160
Thailand

Dr. Pritha Ghosh
Indian Institute of Chemical Biology
India

Prof. Debnath Bhattacharyya
Hannam University,
Daejeon,
Korea

Dr. Khaled Abu-Amero
College of Medicine, King Saud University,
Saudi Arabia

Dr. Faiyaz Ahmed
Department of Studies in Food Science and Nutrition
University of Mysore,
India
Editorial Board

Prof. Rama Devi Mittal
Sanjay gandhi PGI Lucknow
India

Prof. Kai Li
Suzhou University uzhou,
Jiangsu,
China

Dr. Alzta Amiel
Faculty of life Science Bar-ilan Ramat-Gan,
Israel

Dr Olufemi Oloyede
Department of Obstetrics and Gynaecology,
Olabisi Onabanjo University Teaching Hospital
Sagamu,
Ogun State,
Nigeria

Dr. Vishwanathan Hucthagowder
Washington University school of medicine
USA

Dr. Abdellah S. Gounni
Faculty of Medicine,
University of Manitoba
Canada

Prof. Ruixing Yin
Department of Cardiology, Institute of Cardiovascular Diseases,
Guangxi Medical University
22 Shuangyong Road,
Nanning 530021,
Guangxi,
China

Dr. Guangming Han
Georgia State University
USA

Dr. C. Emmanuel
Global Hospitals Group
India

Dr. Alessio Squassina
Department of Neuroscience,
University of Cagliari
Italy

Dr. Jiexiong Feng
Department of Pediatric Surgery, Tongji Hospital,
Huazhong University of Science and Technology
China

Dr. Magdy Abd ElRehim Sayed Aly
Faculty of Science,
Beni Suef University
Egypt

Dr. Hamid Jafarzadeh
Mashhad Faculty of Dentistry and Dental Research Center
Iran

Dr. Youse Rasmi
Department of Biochemistry,
Faculty of Medicine,
Urmia University of Medical Sciences,
Urmia,
Iran

Dr Keya Chaudhuri
Indian Institute of Chemical Biology
India

Ivan Y. Torshin
Computational Center of The Russian Academy of Sciences
Russia

Dr. Wagdy K. B. Khalil
National Research Centre (NRC)
Egypt

Dr. Keya Chaudhuri
Indian Institute of Chemical Biology
India

Dr. A.Chandrasekar
Anthropological Survey of India,
Southern Regional Bogadi 2nd stage,
Mysore-570 026
India

Dr Raghavendra Babu YP
Kasturba Medical College, Mangalore
India

Dr. Shayesteh Jahanfar
Royal College of Medicine, Perak;
University of Kuala Lumpur
Malaysia

Prof. Wei Wang
Capital Medical University, Beijing, China;
Chinese Academy of Sciences, Beijing, China
China
Instructions for Author

Electronic submission of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The cover letter should include the corresponding author's full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author's surname, as an attachment.

Article Types
Three types of manuscripts may be submitted:

Regular articles: These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

Short Communications: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

Reviews: Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

Review Process
All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review. Decisions will be made as rapidly as possible, and the journal strives to return reviewers' comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the JMGG to publish manuscripts within weeks after submission.

Regular articles
All portions of the manuscript must be typed double-spaced and all pages numbered starting from the title page.

The Title should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited. Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard Abbreviations should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

The Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

Materials and methods should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail.
Results should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors' experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

The Discussion should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

The Acknowledgments of people, grants, funds, etc should be brief.

Tables should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

Figure legends should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

References: In the text, a reference identified by means of an author's name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author's name should be mentioned, followed by 'et al'. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like 'a' and 'b' after the date to distinguish the works.

Examples:
Abayomi (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 1992), (Chege, 1998; 1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001)
References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:

Short Communications
Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage.
Fees and Charges: Authors are required to pay a $550 handling fee. Publication of an article in the Journal of Neuroscience and Behavioral Health is not contingent upon the author's ability to pay the charges. Neither is acceptance to pay the handling fee a guarantee that the paper will be accepted for publication. Authors may still request (in advance) that the editorial office waive some of the handling fee under special circumstances.

Copyright: © 2012, Academic Journals. All rights Reserved. In accessing this journal, you agree that you will access the contents for your own personal use but not for any commercial use. Any use and or copies of this Journal in whole or in part must include the customary bibliographic citation, including author attribution, date and article title.

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

Disclaimer of Warranties

In no event shall Academic Journals be liable for any special, incidental, indirect, or consequential damages of any kind arising out of or in connection with the use of the articles or other material derived from the JNBH, whether or not advised of the possibility of damage, and on any theory of liability.

This publication is provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication. While every effort is made by Academic Journals to see that no inaccurate or misleading data, opinion or statements appear in this publication, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Academic Journals makes no warranty of any kind, either express or implied, regarding the quality, accuracy, availability, or validity of the data or information in this publication or of any other publication to which it may be linked.
<table>
<thead>
<tr>
<th>ARTICLES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Case Report</strong></td>
</tr>
<tr>
<td><strong>Recurrent giant malignant peripheral nerve sheath tumor of the scalp with intracranial extension</strong></td>
</tr>
<tr>
<td>R.S. Jaggi, S. Mehta and S. Pasricha</td>
</tr>
<tr>
<td><strong>Research Articles</strong></td>
</tr>
<tr>
<td><strong>Differential behavioral outcome of anxiety tests in runner rats treated with corticosterone</strong></td>
</tr>
<tr>
<td>Suk-Yu Yau, Benson Wui-Man Lau, Tatia M. C. Lee and Kwok-Fai So</td>
</tr>
<tr>
<td><strong>Psychiatric symptoms and disorders in seizure cases referred to psychiatric out-patient service</strong></td>
</tr>
<tr>
<td>Shakya Dhana Ratna</td>
</tr>
</tbody>
</table>
Recurrent giant malignant peripheral nerve sheath tumor of the scalp with intracranial extension

R .S. Jaggi1*, S. Mehta2 and S. Pasricha3

1Department of Neurosurgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector V, Rohini, New Delhi, India.
2Department of Plastic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector V, Rohini, New Delhi, India.
3Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Sector V, Rohini, New Delhi, India.

Accepted 7 March, 2013

Malignant peripheral nerve sheath tumors (MPNSTs) are rare neoplasms, usually arising from somatic soft tissues or peripheral nerves. The incidence of MPNSTs is approximately 0.001% in the general population. MPNSTs are mainly located in the buttocks, thighs, brachial plexus, and paraspinal region. Scalp is an unusual and surgically challenging site of occurrence. We report a case of giant recurrent MPNST in the left fronto-parietal region, with intracranial extension, in a 58 year old female which was excised completely along with the involved overlying skin, and reconstruction was done for the bony and skin defect. She was given adjuvant radiotherapy. She is doing well after treatment and is in regular follow up. MPNST should be considered by neurosurgeons in the differential of an enlarging scalp soft-tissue lesion with bony and intracranial involvement. Scalp MPNSTs are mostly aggressive lesions, and multimodality approaches are necessary to optimize outcomes.

Key words: Malignant peripheral nerve sheath tumors (MPNST), scalp, intracranial, surgery.

INTRODUCTION

Malignant peripheral nerve sheath tumors (MPNSTs) are rare neoplasms, usually arising from somatic soft tissues or peripheral nerves. The incidence of MPNSTs is approximately 0.001% in the general population (Ali-Gahtamy et al., 2005). MPNSTs are mainly located in the buttocks, thighs, brachial plexus, and paraspinal region (Wanebo et al., 1993). To the best of our knowledge, only 3 cases of MPNSTs of the scalp with intracranial extension have been reported in the English literature (Garg et al., 2004; Ge et al., 2010; Kumar et al., 2007).

We report a case of giant recurrent MPNST in the left fronto-parietal region, with intracranial extension, in a 58 year old female which was excised completely along with the involved overlying skin and bony reconstruction was done for the bony defect.

CASE REPORT

A 58 year old female presented to us with progressive right sided weakness for the past 3 months along with a gradually increasing nodular swelling in the left parietal scalp. The patient was operated 22 years ago for the swelling at the same site with surgical excision, and bony removal and was advised adjuvant radiotherapy which the patient did not undergo. The details of the previous treatment including the biopsy report were not available to us. She remained asymptomatic for all these years till 3 months back when she started having the present problem. On examination, she was conscious, and oriented with normal higher mental functions. There was a right upper motor neuron type facial involvement. She had right hemiparesis with a power of 0/5 in the right upper limb and 2/5 in the right lower limb. Local examination revealed a 3 × 3 cm hard nodular swelling in the left parietal scalp with erythematous and indurated overlying skin, fixed to the underlying mass. There was a 5 × 5 cm sized bony defect in the left fronto-parietal region reaching midline, and previous surgical scar was healthy.

The brain magnetic resonance imaging (MRI) revealed a 7 × 6 × 6 cm sized extraxial lobulated mass lesion in the left fronto-parietal region, hypointense on T1 weighted images and hyperintense on T2 weighted images with...
homogenous enhancement on contrast administration, compressing the brain parenchyma and growing out of the bony defect involving the overlying skin (Figure 1; a and b). The patient was investigated for any lesion elsewhere in the body but none was found. The patient underwent exploration via previous scalp incision and complete surgical excision of the lesion, along with removal of overlying involved skin with cranioplasty for bony defect with methylmethacrylate and closure of the scalp defect with transpositioned scalp flap from right fronto-parietal region and split skin grafting.

Post-operative computated tomography (CT) head showed complete excision of the mass (Figure 2). The patient improved neurologically after surgery. The biopsy report showed proliferation of spindle cells with mild pleomorphism in interlacing fascicles, with alternating hypercellular and hypocellular areas (marbelized effect), with cartilaginous metaplasia and buckling of nuclei corresponding to schwannian differentiation. No significant mitoses or necrosis was seen. On immunohistochemistry, the tumor cells were positive for vimentin and S-100, and negative for EMA, CK, CD34 and SMA, and a final diagnosis of MPNST was established (Figure 3). She was given adjuvant radiotherapy and has been in regular follow up for 2 months and is fine.

**DISCUSSION**

As defined by the World Health Organization, MPNSTs are malignant tumors arising from a peripheral nerve or showing a nerve sheath differentiation, with the exception of tumors originating from the epineurium or the peripheral nerve vasculature (Kumar et al., 2007). These tumors are treated as a subcategory of soft tissue sarcomas, in which they comprise 3 to 10% of all such tumors (Al-Gahtamy et al., 2005). MPNSTs are associated with genetic alterations such as NF1 loss of heterozygosity.

Approximately one-third of MPNSTs arise de novo, whereas the remainder represent a sarcomatous degeneration of a pre-existing plexiform neurofibroma in a neurofibromatosis I or non-neurofibromatosis I patient (World Health Organization, 2000). In present case, as the previous biopsy report was not available, we presume that it was a primary scalp MPNST involving the underlying bone which was excised 22 years ago and which recurred. There were no features of neurofibromatosis I in the present case. MPNSTs usually occur in the third to sixth decades of life and usually affect the medium and larger nerves. Tumor location has been found to be a strong prognostic factor with those in the thoracic and retroperitoneum having worse outcomes (Wanebo et al., 1993). Histopathologically, these are highly cellular tumors that characteristically show a fascicular pattern, spindle-shaped nuclei, and scant cytoplasm. The majority of tumors show geographic necrosis and mitotic activity. Most features were seen in this case, except for mitosis and necrosis.

Magnetic resonance imaging is the investigation of

---

**Figure 1.** (a) Preoperative MRI brain contrast enhanced T1 weighted axial image showing a large extra axial lobulated left fronto-parietal mass lesion compression the brain parenchyma with resultant mass effect. (b) Preoperative MRI brain contrast enhanced T1 weighted sagittal image showing a large extra axial lobulated left fronto-parietal mass lesion compression the brain parenchyma with resultant mass effect along with involved overlying skin.
Choice because it reveals the nerve origin and the relationship to adjacent structures in most cases (Al-Gahtamy et al., 2005). The International Consensus Group has recommended that the current management of MPNST should be identical to that of any other soft tissue tumors. Adjuvant radiation therapy (RT) should be considered for all intermediate- and high-grade lesions, as well as low-grade tumors with positive margins and was given in this case as well (Angelov et al., 1998; Vege et al., 1994). Local recurrences have been reported to vary from 52 to 88.9% for different sites, whereas metastasis (mainly in the lungs and liver) ranged from 11.1 to 18%. The 5-year survival rate among patients with MPNSTs ranges from 30 to 50% (Angelov et al., 1998; Ferner and Gutmann, 2002; Vege et al., 1994). In this case, it recurred locally and there was no metastatic lesion elsewhere in the body.

In view of the high incidence of local recurrence in MPNSTs after surgery, adjuvant postoperative RT has been shown to improve local control. This could be explored further, especially in sites in which complete surgical resection may not always be feasible (for example, the scalp) with intracranial extension (Kumar et al., 2007; Wilson et al., 1994). With MPNSTs being relatively radioresistant, similar to soft tissue sarcomas, an attempt should always be made for near total surgical debulking of the tumors, and adjuvant postoperative RT could help to reduce the local recurrence.

**Conclusion**

MPNST should be considered by neurosurgeons in the differential of an enlarging scalp soft-tissue lesion with bony and intracranial involvement. Scalp MPNSTs are mostly aggressive lesions, and multimodality approaches are necessary to optimize outcomes.

**REFERENCES**

Full Length Research Paper

**Differential behavioral outcome of anxiety tests in runner rats treated with corticosterone**

Suk-Yu Yau¹, ², ³, Benson Wui-Man Lau¹, ², Tatia M. C. Lee², ⁴, ⁵, ⁶ and Kwok-Fai So¹, ², ³, ⁷*

¹Department of Anatomy, Li Ka Shing Faculty of Medicine, University of Hong Kong, SAR, Hong Kong.
²State Key laboratory of Brain and Cognitive Science, Li Ka Shing Faculty of Medicine, University of Hong Kong, SAR, Hong Kong.
³Research Centre of Heart, Brain, Hormone and Health Aging, SAR, Li Ka Shing Faculty of Medicine, University of Hong Kong, SAR, Hong Kong.
⁴Laboratory of Neuropsychology, University of Hong Kong, SAR, Hong Kong.
⁵Institute of Clinical Neuropsychology, University of Hong Kong, SAR, Hong Kong.
⁶Laboratory of Cognitive Affective Neuroscience, University of Hong Kong, SAR, Hong Kong.
⁷JGHM Institute of CNS Regeneration, Jinan University and The University of Hong Kong, Guangzhou, China

Accepted 4 December, 2012

Both clinical and pre-clinical studies have suggested that physical exercise is beneficial for lowering anxiety. However, some animal studies fail to demonstrate the anxiolytic effect of physical exercise. The inconsistencies among studies may be due to differences in animal models and behavioral tests. Previously, injection of corticosterone (CORT) for 14 days induced depression-like behavior to varying based on was shown. Animal model was used to investigate whether CORT treatment induced anxiety-like behavior and to examine the anxiolytic effect of voluntary running using two behavioral measurements: open field test and elevated plus maze. Results indicated that running reduced anxiety-like behavior in vehicle-treated animals in both tests. Treatment with CORT showed a significant anxiogenic effect in the open field test regardless of the doses, but not in the elevated plus maze. Running reduced anxiety in the open field test, but showed no effect in elevated plus maze in the CORT-treated rats. The data suggest the discrepancy of these two anxiety-related measures in the animal model of stress.

**Key words:** Corticosterone (CORT), stress, voluntary running, open field test, elevated plus maze, anxiety-like behavior.

**INTRODUCTION**

Hippocampus is not only involved in cognitive functions, but also plays an important role in emotional regulation (Mac, 1949) and anxiety state (Bannerman et al., 2004). In our daily life, we always face challenges that are anxiogenic, for example sitting for an examination, job interviews and public presentations. Anxiety is a normal response to a stressor that helps an individual to promptly cope with the demanding situation. Anxiety disorder presents as an excessive pathological form of fear consisting of a fear state with excessive reaction for the actual threat. Anxiety disorder frequently presents in clinical psychiatry with a 30% occurrence rate. In addition, patients with co-occurring symptoms of anxiety always show worsened severity of depression (Mineka et al., 1998).

In animal studies, it has been shown that exposure to acute uncontrollable stressors cause a variety of behaviors called learned helplessness such as exaggerated shock elicited freezing; deficits in shuttle box escape learning. These kinds of stress responses have been suggested to represent the animal analogs of human anxiety (Maier and Watkins, 1998). Physical exercise is known to reduce the signs and symptoms of anxiety disorder and depression with support from a number of human studies (Dun et al., 2001; Merali et al., 2003;
Blumenthal et al., 2007). Recently, it has been reported that exercise could exert similar anxiolytic effect as antidepressant treatment in animals (Duman et al., 2008). Preventative and curative effects of physical exercise in depression- and anxiety-like behaviors in animal model have also been reported (Binder et al., 2004; Dulawa et al., 2004). In vehicle-treated rats, four or eight weeks of wheel running is able to alter anxiety behavior in the open field test, but not in the elevated plus maze (Burghardt et al., 2004). Chronic running (6-week) reduces anxiety-like behaviors in terms of exaggerated shock-elicited freezing and shuttle box escape deficits in rats exposed to uncontrollable stress (McKinney and Bunney, 1969). However, inconsistent effects of exercise in the animal models of anxiety have also been found in different studies in which animals with voluntary wheel running show anxiolytic effect (Duman et al., 2008; Salam et al., 2009), no effect (Chiang et al., 2010) or anxiogenic effect (Burghardt et al., 2004). The differences in animal models (normal or stressed animals), animal species, and behavioral tests may contribute to the inconsistencies among those studies.

Psychiatric patients suffering from depressive disorders are often associated with hyperactivation of hypothalamus-pituitary-adrenal axis (HPA axis) that leads to elevated plasma corticosteroids. Animal models with repeated stress have been widely used to study the neurobiological changes following stress exposure (Nestler et al., 2002). However, this model may increase the experimental variability since individual differences in the activation of HPA axis in response to stress exposure may result in different levels of CORT elevation among different individuals exposed to the same stressor. The alternative way is to use repeated exogenous CORT administration as a mean to mimic the effect of stress that associated with elevated CORT levels. This model could provide an effective control over the increases in blood CORT levels in the animals and increase depression-like behavior in rats in a dose-dependent manner (Yau et al., 2011b).

However, exogenous administration of CORT has been reported to both increase (Calvo et al., 1998) or decrease (Andreatini and Leite, 1994) the anxiety level in the elevated plus-maze. It is unclear whether the discrepancy is due to dose effect of CORT treatment. It has previously been reported that treatment with different doses of CORT for 14 days produced a graded increase in depression-like behavior and plasma CORT level (Yau et al., 2011b). Furthermore, wheel running or antidepressant treatment could counteract CORT-induced depression-like behavior and depression-impaired memory in the rats. Since there is no experimental data on measuring anxiety-like behavior in animals treated with different doses of CORT, in the present paper, we used different doses of CORT administrations to examine whether there was an increase in anxiety-like behavior in CORT-treated rats; and to characterize the effects of voluntary running on anxiety-related behaviors in the open field test and the elevated plus maze (the two behavioral paradigms that are commonly used in anxiety tests).

In vehicle-treated rats, the results showed that voluntary running reduced anxiety-like behaviors in the open field test and elevated plus maze. In the CORT-treated rats, the anxiety level was significantly increased by CORT treatment and decreased by running in the open field test. However, in the elevated plus maze, neither CORT treatment nor voluntary running affected the anxiety level in the CORT-treated rats. The data may indicate a discrepancy in measuring the anxiety-like behavior between the open field tests and elevated plus maze in the CORT-injected rat model of stress.

**MATERIALS AND METHODS**

**Animal group and treatment**

Adult Sprague Dawley (250 ± 20 g, 6 to 7 weeks old) male rats were obtained from the Laboratory Animal Unit, University of Hong Kong. All experimental procedures were approved and followed the guidelines of the Committee on the Use of Live Animals in Teaching and Research, University of Hong Kong. Rats were kept on a 12 h light-dark cycle with ad libitum access to food and water. The animals were divided into runner and non-runner groups and were treated with different doses of CORT (30, 40 and 50 mg/kg) or sesame oil for 14 days (n = 8 to 10/group). The day after the CORT treatment (day 15), the rats were subjected to the open field test and elevated plus maze to examine anxiety-like behavior.

**Corticosterone (CORT) treatment**

CORT (Sigma-Aldrich, USA) at different doses (30, 40 and 50 mg/kg) and sesame oil were prepared and injected subcutaneously according to the method of Hellsten et al. (2002). The dose of 40 mg/kg has been reported to elevate blood levels of CORT over a 24 h period (Sapolsky et al., 1985). A stock of CORT emulsion was prepared by suspending CORT in sesame oil, followed by vortex and sonication. Injection (0.8 ml/rat) was made subcutaneously in the neck region daily at 4:00 p.m. The CORT treatment was started at the same time when the rats were allowed to run. The control rats received daily injections of sesame oil.

**Voluntary wheel running**

Runner rats were housed singly in polyethylene cages equipped with running wheels (diameter, 31.8 cm; width, 10 cm; Nalgene Nunc International, NY). Animals were allowed to familiarize with living condition with locked wheels for 3 days prior to the treatment. The locked wheels were then unlocked for 14 days in the runner groups or kept locked for the non-runner groups. Wheel revolutions were recorded by computer using VitalViewer software (Mini Mitter Company, Inc, OR). Non-runners were housed with locked running wheels in cages identical to that of runners.

**Open field test**

The behavioral test was conducted in a quiet and dimmed room with constant illumination; the test was performed from 2:00 to 4:00 p.m. After 2 h of habituation in the test room, each rat was individually placed into the center of the open field arena (90 × 90
Elevated plus maze

Each rat was tested in the elevated plus maze 2 h after the open field test in the same room under the same lighting condition. The elevated plus-maze consisted of four arms made of Plexiglas, elevated 50 cm above the floor. Two arms were open (0.5 cm high edges), while the other two arms were enclosed with 36 cm high walls. Each animal was placed onto the center of the apparatus facing an open arm and was then evaluated for 5 min test. The maze was wiped with 70% ethanol and dried between each trial. The behavior was recorded with a video camera and then analyzed using Smart Junior system (Panlab, Spain). Anxiety-like behavior was evaluated through percent time spent in open and closed arms.

Statistical analysis

Two-way analysis of variance (ANOVA) with CORT treatment and running as between-subject factors was performed with Fisher's LSD post-hoc test. A repeated measure ANOVA was applied for analyzing body weight change and running activity over the 14-day treatment period. Student's t-test was only applied for comparison between vehicle-treated non-runners and runners. The statistical difference was determined with P-value < 0.05. Data were presented as mean± standard error of mean (SEM).

RESULTS

Change of body weight and adrenal gland weight

Weight loss of the adrenal gland which occurs after CORT treatment indicates the efficacy of subcutaneous injections of CORT. Repeated measures of ANOVA revealed a significant change in body weight gain during the 14-day treatment period (Figure 1a and b), effect of day: F\(_{5,67} = 19.2\), P = 0.00090). Significant interaction between day and CORT treatment on body weight change was also observed (day X CORT: F\(_{3,57} = 44.9\), P = 0.00053). CORT treatment and running decreased body weight gain during the treatment (effect of CORT: F\(_{3,57} = 57.2\), P = 0.0077; effect of running: F\(_{1,57} = 7.7\), P = 0.00050). The adrenal gland weight was expressed as the ratio of adrenal gland weight to body weight. Two-way ANOVA indicated that the ratio of adrenal gland to body weight was significantly decreased by CORT treatment (effect of CORT: F\(_{3,57}=142.7\), P=0.00033) (Figure 1c), but was not affected by running (effect of running, F\(_{1,57} = 1.1\), P = 0.300).

Running activity of CORT-treated runners

Repeated measures ANOVA indicated that all rats increased their running activity during the treatment period (Figure 2: F\(_{3,38} = 14.8\), P = 0.00042). The runners showed increased running activity during the treatment period (effect of day: F\(_{3,38} = 5.8\), P = 0.0060). Runners with CORT treatment showed a relative higher running activity when compared to runners with vehicle treatment; however, there was no significant effect of CORT on increasing running activity (effect of CORT: F\(_{3,38} = 1.4\), P = 0.29).

Running and CORT treatment did not affect locomotor activity in the rats

Results showed that neither CORT treatment nor running for 14 days affected traveling distance (Figure 3a: effect of running: F\(_{1,50} = 1.0\), P = 0.75; effect of CORT: F\(_{3,50} = 1.8\), P = 0.16) and travelling speed (Figure 3b: effect of running: F\(_{1,50} = 1.4\), P = 0.24; effect of CORT: F\(_{3,50} = 1\), P = 0.15) in the open field test. This data suggests that the difference in anxiety-like behavior was not an artifact of altered locomotor activity following CORT treatments.

Anxiety behavior of the CORT-treated runners and non-runners in the open field test

Anxiety-like behavior of the rats was tested in the open field test and elevated plus maze following the 14-day treatment. In the open field test, CORT, nor running showed no significant effect on the time spent in the central area (Figure 3c: effect of CORT: F\(_{3,56} = 0.8\), P = 0.52; effect of running: F\(_{1,56} = 1.4\), P = 0.25). However, there was a relative increase in time spent in the central area in the vehicle-treated runners when compared with the vehicle-treated non-runners (student's t-test, P<0.05), indicating running reduced anxiety level in the vehicle-treated rats.

Time spent in the peripheral area was increased by CORT (Figure 3d: effect of CORT: F\(_{3,47} = 3.0\), P = 0.042). Post hoc analysis showed that the rats treated with 30 and 40 mg/kg CORT demonstrated a significant increase in time spent in the peripheral area when compared with the vehicle-treated rats (P<0.05). The main effect of running was also observed (effect of running: F\(_{1,47} = 16.7\), P = 0.00021), indicating running decreased anxiety level in CORT-treated rats in the open field test. There was a significant decrease in time spent in the peripheral area in the vehicle-treated runners when compared with the vehicle-treated non-runners (student's t-test, P<0.05).

Effect of CORT and running on anxiety-like behavior in elevated plus maze

There was no significant effect of CORT and running on the locomotor behavior in the elevated plus maze (data not shown). Running and CORT treatment was ineffective
Control         30            40            50   
                    Dose (mg/kg) 
Adrenal to body weight ratio 
(mg/g)

Figure 1. Change of body weight and adrenal weight of the CORT-treated runners and non-runners. (a and b) Body weight gain was significantly decreased by CORT treatments in the non-runners and runners. Running reduced body weight gain. (c) Adrenal to body weight ratio was an indicator for the efficacy of CORT administration. A significantly decreased adrenal weight was found in the CORT-treated rats when compared with the vehicle-treated rats. Ctrl: Vehicle treatment; 30, 40 and 50 mg: doses of CORT per body weight (kg). N: non-runners; R: runners. Value are represented as mean±SEM. *P < 0.005 compared to the vehicle-treated group.

Figure 2. Voluntary running activity of the CORT- and vehicle-treated rats. The running activity was increased in the first week, and was then maintained at the level of 2 to 4 km/day. The rats treated with CORT showed a relatively higher running activity as compared to the vehicle-treated control. Data are expressed as daily mean running distance (m) per day mean ± SEM.

ineffective in altering the time spent in the open arms (Figure 4a: effect of running: F_{1,51} = 0.1, P = 0.71; effect of CORT: F_{3,51} = 0.6, P = 0.63) and in the closed arms (Figure 4b: effect of running: F_{1,54} = 1.5, P = 0.23; effect of CORT: F_{3,51} = 0.4, P = 0.34). The CORT-treated runners and non-runners did not show an increase or decrease in time spent in the open arms and closed arms, indicating that CORT treatment alone or running in CORT-treated rats did not exert effects on anxiety-like behavior in the elevated plus maze. Furthermore, CORT treatment showed no effect on time spent in the center (Figure 4c: effect of CORT: F_{1,51} = 1.11, P = 0.35). Conversely, running showed a main effect on time spent in the center (effect of running: F_{1,51} = 6.06, P = 0.018). Running showed an anxiolytic effect in the vehicle-treated runners as evidenced by relatively decreased percentage of time spent in the closed arms, and increased time spent in the open arms when compared with the vehicle-treated non-runners (student’s t-test: P < 0.05).

DISCUSSION

In the present study, we used the open field test and elevated plus maze to examine: (1) whether different doses of repeated CORT treatment could induce anxiety-
Figure 3. Locomotor activity and anxiety-like behavior of runners and non-runners in the open field test. (a) CORT treatment did not affect locomotor activity in the runners and non-runners. There was no significant difference in the mean speed of the CORT-treated runners and non-runners. (b) Total distance in the arena of the CORT-treated rats remained in the similar level as the vehicle-treated rats. (c) The CORT-treated rats showed no difference in time spent in the central area of the arena when compared with the vehicle-treated rats. However, running significantly increased the time spent in the central area in the vehicle-treated rats, but not the CORT-treated rats. (d) Rats treated with CORT showed increased time spent in the peripheral area. Runners showed a significant decrease in time spent in the peripheral area of the arena when compared to the non-runners. The vehicle-treated runners showed significantly decreased time spent in peripheral areas when compared with the vehicle-treated non-runners. Student’s t-test: *P < 0.05 compared to the vehicle-treated non-runners. One-way ANOVA: **P < 0.05 compared to the vehicle-treated rats.

like behaviors; and (2) the counteractive effect of voluntary wheel running on CORT-induced anxiety-like behavior. The vehicle-treated runners showed an increase in time spent in the center of the open field test, in the open arm and the center of the elevated plus maze, respectively.

The findings confirmed that voluntary running for two weeks was associated with a reduced anxiety-like behavior as previously shown in the vehicle-treated rats by other group (Salam et al., 2009). However, CORT treatment increased anxiety level in the open field test, but not in the elevated plus maze. The results raise the question on the discrepancy between these behavioral tests for anxiety-like behavior in animal model of stress.

Although exercise has been shown to reduce anxiety in humans (Dunn et al., 2001; Manger and Motta, 2005) and in exercised animals (Binder et al., 2004), some studies fail to show the anxiolytic effect of exercise (Burghardt et al., 2004; Chiang et al., 2010). Contradictory results on the effects of exercise on anxiety behavior have been reported in some animal studies (Andreata and Leite, 1994; Calvo et al., 1998). Contradictory results are also found in the open field test and elevated plus maze, for example, same mouse strain was defined as anxious in the elevated plus maze, but non-anxious in the open field test (Trullas and Skolnick, 1993, Rogers et al., 1999). Although these two tests are commonly applied to examine anxiety-like behavior in the animals, the differences in anxiogenic property of these two apparatuses have been reported. Carola et al. (2002) suggested that
Figure 4. Running decreased anxiety-like behaviour in the vehicle-treated rats, but not CORT-treated rats in the elevated plus maze. Running and CORT treatment did not affect the percentage time spent in the open arms (a) and closed arms (b), respectively. Student’s t-test revealed significant increases in time spent in open arms and center (c), and a decrease in time spent in closed arm in the vehicle-treated runners when compared to vehicle-treated non-runners. *P < 0.05 compared to runner counterpart by student’s t-test.

Discrepancies between these two tests may be due to differences in analyzing criteria among different studies or it is possible that the elevated plus maze may be more anxiogenic to experimental animals than the open field test.

Aversive stress in the open field test is mainly due to the novelty in a new environment, whereas aversive stress in the elevated plus maze is due to novelty and the height of the maze that comprise the behavior of risk assessment during the test, suggesting a stress coping to the animals during the test (Rodgers, 1997). In the elevated plus maze, the animals are placed in the centre of the plus maze as the starting point where animals initially engage in high level of risk assessment, therefore, the design of the elevated plus maze offers more choices and causes a higher level of stress to the animals as compared to the open field test. Nosek et al. (2008) conclude that the differences in the stressfulness between the open field test and elevated plus maze may contribute to the differential outcome. Nosek et al. (2008) suggested that the open field test would be a better measure of passive coping, while the elevated plus maze would be a more sensitive measure of active coping in response to stress.

A consistent result was observed in the vehicle-treated rats that running reduced anxiety level in both the elevated plus maze and open field test. The differential behavioral outcome between these two tests in the CORT-treated rats may suggest a differential stress response between these two tests in our CORT-injected rats. Pre-exposure to the open field test may contribute as a confounding effect since pre-exposure to different novel environment (e.g. the open field) immediately before testing in the elevated plus maze may alter the motor activity in the elevated plus maze and lead to a greater preference of entering the open arms of the maze.
(Pellow et al., 1985). However, Walf and Frye (2007) reported that pre-exposure to other testing environment does not alter subsequent behavior of rats and mice in the elevated plus maze. To avoid any possibility of different experience or stressor exposure altering the behavior of rats in the elevated plus maze, the rats were left in the transport cages for 2 h before testing to ensure that the experimental rats have similar level of stress exposure before the behavioral test. Therefore, it is unlikely that the order effect will be a confounding variable to our study. Prut and Belzung (2003) suggested that the open field test is not a valid test for anxiety as it is not sensitive to some effective compounds (e.g. alprazolam and selective serotonin reuptake inhibitor (SSRI)) in treating anxiety disorders, they also concluded that the open field test may be a test for rodent model of normal anxiety.

Increased open field locomotion and decreased anxiety measures following wheel running have been found in the animals after 24 h of wheel running (Dishman et al., 1996; Burghardt et al., 2004). In this study, there was no difference in locomotor activity between the CORT-treated runners and non-runners as indicated by similar activity levels in the open field test and elevated plus maze, though there was a higher running activity in the CORT-treated rats as compared to the vehicle-treated rats.

The presented data shows that CORT treatment significantly increased anxiety-like behavior (increased time spent in peripheral) in the open field test regardless of the doses of CORT treatment, but not in the elevated plus maze. The counteractive effect of running on reducing anxiety-like behavior in CORT-treated rats was only observed in the open field test, but not in elevated plus maze. Gregus et al. (2005) reported that CORT (40 mg/kg) treatment for 21 days in non-running rats significantly increased immobility time in the forced swim test, but showed minimal effect on anxiety-like behavior in the open field test. The hippocampus has been known to play a crucial role in anxiety and depression. The dorsal and ventral hippocampi exhibit discrete functions in regulating learning and emotion, respectively. It has been reported that lesions of dorsal hippocampus led to relatively a weak anxiolytic-like effect, while lesions of ventral hippocampus produced a robust anxiolytic-like effect (Bertoglio et al., 2006; Pentkowski et al., 2006). Recently, it has been suggested that adult neurogenesis in the dorsal and ventral hippocampus might function in a dissociated way (Duncko et al., 2007) in which the dorsal hippocampus is likely specialized for memory functions, whereas the ventral hippocampus is dedicated to anxiety functions (Engin and Treit, 2007). Our previous study showed that physical exercise in terms of running wheel could protect the animals from detrimental effects of CORT via restoring adult neurogenesis and dendritic atrophy in the dorsal part of the hippocampus (Yau et al., 2011a). Several studies reported that a decrease in hippocampal neurogenesis is associated with an increase in anxiety-related behaviors (Ageta et al., 2008; Bergami et al., 2008; Revest et al., 2009). In particular, Revest et al. (2009) demonstrated an increased anxiety-like behavior in transgenic mice with an inducible reduction in neurogenesis throughout the rostro-caudal axis of the dentate gyrus. It is possible that depressive behavior and memory impairment is more dependent on the dorsal part of the hippocampus, while anxiety behavior is more dependent on the ventral part of the hippocampus.

We have previously reported that the dorsal hippocampal neurogenesis was increased in rats with two-week voluntary wheel running (Yau et al., 2011b). This study demonstrated that running decreased anxiety-like behavior in vehicle-treated rats; the promoting effect of running on adult neurogenesis and structural changes in the ventral hippocampus could possibly contribute to the observed effects of wheel running in our vehicle-treated rats. However, this speculation warrants further investigation with examination on the effects of specific blockade of ventral or dorsal hippocampal neurogenesis on emotional behavior.

In summary, these results have demonstrated that voluntary running reduced anxiety-like behaviors in the vehicle-treated rats in two behavioral paradigms: the open field test and the elevated plus maze. The CORT treatment increased anxiety level in the open field test, but showed an effect in the elevated plus maze. Running primarily reduced anxiety-like behavior in the open field test, but not in the elevated plus maze in the CORT-treated rats. The data indicated a differential anxiety-like behavior measured by these two tests in the CORT-treated rats. Extra attention should be given to the discrepancy of these two anxiety-related measures in animal model of stress since the physiological basis of anxiolytic effect of exercise will only be revealed with consistency of effects of exercise across the anxiety-related measures.

ACKNOWLEDGEMENTS

The authors thank Mr. Peter Ksiazek and Ms. Jennifer Graham for their help in proofreading the manuscript, and Mr. Bolton Chau for his comments on statistical analysis. This study was supported by funding from Jessie Ho Professorship in Neuroscience (The University of Hong Kong Foundation for Educational Development and Research Limited), the National Natural Science Foundation of China, the Areas of Excellence (AoE) Scheme established under the University Grants Committee of the Hong Kong and AoE Matching Fund from the University of Hong Kong and the Fundamental Research Fund for the central universities (21609101, KF SO).

REFERENCES

Ageta H, Murayama A, Migishima R, Kida S, Tsuchida K, Yokoyama M,


Bertoglio LJ, Joca SR, Guimaraes FS (2006). Further evidence that anxiety and memory are regionally dissociated within the hippocampus. Behav. Brain Res.175:183-188.


Psychiatric symptoms and disorders in seizure cases referred to psychiatric out-patient service

Shakya Dhana Ratna

Department of Psychiatry, B P Koirala Institute of Health Sciences, Nepal. E-mail: drdhanashakya@yahoo.com.
Tel: 977-025-525555; ext: 5334, 5347.

Accepted 7 March, 2013

Epilepsy and seizure disorders affect more than 1% adult population. Associated psychiatric problems are reported to increase and worsen the morbidity. In Nepalese context of scant data, this study was conducted to sort-out psychiatric symptomatology and disorders among psychiatry out-patient seizure patients. This hospital-based descriptive study analyzed 100 consecutive seizure patients visiting a psychiatric out-patient service in a 1-year period. Seizure diagnosis was as per clinical evidence and electroencephalography (EEG) findings; psychiatric symptomatology was checked and rated with the help of 'Brief psychiatric rating scale' (BPRS) and psychiatric diagnoses were made according to 'International Classification of Diseases: ICD-10'. In this study, 51% subjects were male. Forty-two patients had family history of significant illness, including seizure in 15% and psychiatric illness in 19%. Forty five percent had ICD-10 diagnosis of ‘mental and behavioural disorders’ and all, including the remaining 55% had significant psychopathology. Mood (mainly depression) and anxiety disorders were the most common psychiatric co-morbidities. The most common BPRS items (besides seizure and related) were: somatic, mood, psychotic, hostility and anxiety symptoms. Hence, seizure may manifest with various psychopathology mainly: somatic, mood, psychotic, hostility and anxiety besides seizure-related (for example disorientation and motor) symptoms. A number of psychiatric disorders, mainly depression co-occur in seizure.

Key words: Epilepsy, mental illness, psychiatric symptoms, seizure.

INTRODUCTION

Seizure disorder or epilepsy is one of the most common neuro-psychiatric disorders, affecting about 1% of population within the age of 20 years, and even more in some parts of the world (Hauser and Annegers, 1993). It is one of the largest neuro-psychiatric contributors of Global Burden of Disease by Disability Adjusted Life Year (DALY) (World Bank, 1993). It may be associated with a range of other disorders; those as a causative factor, and effect or manifestation of seizure itself (Mendez, 2009; Raghuthaman et al., 2005; Lishman, 1998; Engel et al., 1986). Depression (Ettinger et al., 2004; Kanner, 2003), anxiety, and psychotic disorders (Nadkarni et al., 2007) are frequently reported higher than among general population (de Araújo Filho et al., 2007). Seizure is associated also with various syndromes, as a manifestation of seizure itself or as induced by seizure, referred to as 'organic mental disorders', for example psychotic, mood, etc (World Health Organization, 1993; American Psychiatric Association, 2000). Profile of those associated disorders and psychopathology offer the insight into common etiological factors in a particular setting and manifest features, leading to better management and prevention strategies.

We have few local data from Nepal about this common but disabling illness, more so about its co-morbid psychiatric disorders and associated symptoms. Hence, we conducted this cross-sectional descriptive study in the Department of Psychiatry, B. P. Koirala Institute of Health Sciences (BPKIHS), Dhan, Nepal in 2006/2007 to sort-out psychiatric symptomatology and disorders among...
seizure patients.

MATERIALS AND METHODS

This study, with purposive sampling, enrolled 100 consecutive seizure disorder (SD) patients clinically diagnosed or diagnosed with the help of electroencephalography (EEG), and associated with one or other clinically significant/manifest psychopathology for which they came in contact and consulted with the psychiatrist/investigator in the study period of 1 year duration from August, 2006 to July, 2007. Those patients who did not give consent and were severely medically unstable were excluded.

The number of subjects required that is, sample size was calculated by using the formula: \( N = \frac{(1.96)^2 \times P \times (100 - P)}{[P \times \beta]^2} \). Where, \( N \) = number of sample, \( P \) = estimated prevalence and \( \beta \) = beta error, maximum permissible is 20%; the smaller the figure, the better is the power. We took 50% as the estimated prevalence of psychiatric co-morbidities because we came across the range of 30 to 60% for comorbid psychiatric disorder as a whole in literature (Mendez, 2009; Raghuthaman et al., 2005; Lishman, 1998). The subjects were those who had some psychiatric symptom and had come for psychiatric consultation and also because the objective was to study psychopathology profile too, besides the disorder. Hence, keeping the average for estimated prevalence, \( P \) as 50% and \( \beta \) error at 0.2, the calculated sample size was 96, and additional 4% subjects were taken for better representation. Hence, the sample size was taken to be 100. The initial concept was to enroll either minimum of 100 or a sizable number that could be enrolled in 1 year period, whichever would be greater and possible. The estimated sample size could be enrolled in more or less of the stipulated study period.

A brief explanation about the study was given and informed written consent was taken from the subject or significant others. Strict confidentiality of information was maintained. The socio-demographic profile and information about the illness (reason for referral, co-morbid conditions, and psychiatric diagnosis) were recorded on a Performa pre-designed for this study. The detailed psychiatric work-up and necessary investigations were done as per the indication, and their affordability and referrals were made to respective departments. The physical diagnoses were recorded as per the department from or to where the referrals were made. The final psychiatric diagnosis and co-morbidities were made according to the ‘International Classification of Diseases-10’ (ICD-10) (World Health Organization, 1993).

Psychiatric symptomatology were checked, studied and rated with the help of ‘Brief psychiatric rating scales’ (BPRS) (Overall and Gorham, 1962). This scale is physician rated and is one of the most researched instruments in psychiatry. The process of rating with this scale takes about 15 to 30 min. Reliability coefficients of 0.56 to 0.87 have been reported (Sajatovic and Ramirez, 2003). The rating scale was utilized in this study as a symptom check-list since it consists of a wide range of psychopathologies. The psychopathologies were rated on 1 to 7 point Likert scale, 1 being absent and 7 being extreme, by asking with patient or family member and by direct observation during the assessment by the investigator.

In this study, the score of 4 that is, moderate or more has been operationally defined as clinically significant for the item to be included as present. Data were entered into computer and analyzed using ‘Statistical package for social studies’ (SPSS 10) software.

RESULTS

Out of a total of 100 patients, 51 were male (with M: F ratio of almost 1: 1), 42% were married, 56% unmarried and 1% widow(er) and separated each. Average age of the subjects was 24.08 (range: 3, 60) years. Age group (10 to 19 years) constituted the largest proportion of 37%, followed by (20 to 29 years) 31% and (30 to 39 years) 22% (Figure 1). We had subjects of different caste/ethnic groups: 32% Mongol (Rai/ Limbu/ Tamang/ Magar/ Sherpa/ Gurung, etc.), 21% Brahmin, 16% Terai ethnic origin (Mandal, Raya, Jha, Yadav, Shah, Gupta, etc.), 12% Chhetri, 10% dalit/disadvantaged, 6% Newar and 3% Indian. Hindus were the most (78%), followed by Buddhists (12%), Muslims 2%, Christians and Kirat 4% each and 43% came from semi-urban, 29% urban, and 28% rural setting. We also had subjects of diverse professions: students (48%), homemakers (25%), laborers (9%), farmers (8%) and others. One fifth (20%) were illiterate and the subjects were relatively better educated...
better educated as a whole (Figure 2).

Most of the cases were brought or accompanied by family member for psychiatric consultation (Table 1). Almost all (96%) had sudden onset and 90% had episodic course of illness. About one third had illness of less than 1 year. More than two-third had seizure morbidity of 1 to 10 years (Figure 3). Nearly half of the total subjects (46%) reported some stressors preceding the seizure attacks. Relational and health related stressors were among the common ones (Table 2). The most common complaints were directly related to seizures, that is misrecognition and or unresponsiveness due to alteration of consciousness (89%). Other main symptoms were somatic or physical complaints (56%) and mood (43%) symptoms (Table 3).

One third of the subjects had a clinically significant illness in their past history, and more than two fifth (42%) had illness in their blood relatives, including 15% with seizure disorder (Table 4). One third (30%) of all seizure patients reported to abuse psycho-active substances (Figure 4). About one fourth of them had some personality traits and 4% had mental retardation which affected the clinical course of illness (Table 5). About half of these seizure subjects had complex partial seizures and 43% generalized tonic clonic seizures (Figure 5).

All subjects had one or other significant BPRS symptom item. Seizure related symptoms: loss of consciousness
Table 1. Sources of referral.

<table>
<thead>
<tr>
<th>Source of referral</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family members</td>
<td>69</td>
</tr>
<tr>
<td>Internal Medicine</td>
<td>11</td>
</tr>
<tr>
<td>Emergency</td>
<td>4</td>
</tr>
<tr>
<td>Family medicine OPD</td>
<td>4</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>3</td>
</tr>
<tr>
<td>Gynecology/Obstetric</td>
<td>1</td>
</tr>
<tr>
<td>Other health centre</td>
<td>1</td>
</tr>
<tr>
<td>Alternative medicine</td>
<td>1</td>
</tr>
<tr>
<td>Relatives/friends</td>
<td>3</td>
</tr>
<tr>
<td>Self</td>
<td>3</td>
</tr>
</tbody>
</table>

OPD: Out-patient department.

Table 2. Types of stressors#.

<table>
<thead>
<tr>
<th>Stressor type</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relational</td>
<td>10</td>
</tr>
<tr>
<td>Relative away</td>
<td>4</td>
</tr>
<tr>
<td>Death of relative</td>
<td>3</td>
</tr>
<tr>
<td>Illness of relative</td>
<td>3</td>
</tr>
<tr>
<td>Study related</td>
<td>4</td>
</tr>
<tr>
<td>Physical illness/health</td>
<td>10</td>
</tr>
<tr>
<td>Environmental</td>
<td>3</td>
</tr>
<tr>
<td>Stopping treatment</td>
<td>4</td>
</tr>
<tr>
<td>Political/social conflict</td>
<td>8</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 3. Presenting complaints#.

<table>
<thead>
<tr>
<th>Complaint</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misrecognition/ Unresponsive</td>
<td>89</td>
</tr>
<tr>
<td>Thought, speech</td>
<td>7</td>
</tr>
<tr>
<td>Substance use</td>
<td>3</td>
</tr>
<tr>
<td>Behavioral problem</td>
<td>29</td>
</tr>
<tr>
<td>Mood symptoms</td>
<td>43</td>
</tr>
<tr>
<td>Anxiety</td>
<td>20</td>
</tr>
<tr>
<td>Perceptual</td>
<td>16</td>
</tr>
<tr>
<td>Somatic/ physical symptoms</td>
<td>56</td>
</tr>
<tr>
<td>Self harm</td>
<td>4</td>
</tr>
<tr>
<td>Personality changes</td>
<td>3</td>
</tr>
<tr>
<td>Others</td>
<td>41</td>
</tr>
<tr>
<td>‘Aunse purne’ (cultural expression)</td>
<td>4</td>
</tr>
</tbody>
</table>

Table 4. Past and family history of illness#.

<table>
<thead>
<tr>
<th>Illness in past</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>67</td>
</tr>
<tr>
<td>Seizure</td>
<td>9</td>
</tr>
<tr>
<td>Neurological</td>
<td>12</td>
</tr>
<tr>
<td>Other medical diseases</td>
<td>4</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>10</td>
</tr>
<tr>
<td>Substance use disorder</td>
<td>1</td>
</tr>
<tr>
<td>Not available</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Illness in family</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>57</td>
</tr>
<tr>
<td>Seizure</td>
<td>15</td>
</tr>
<tr>
<td>Neurological</td>
<td>8</td>
</tr>
<tr>
<td>Other medical diseases</td>
<td>2</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>19</td>
</tr>
<tr>
<td>Substance use disorder</td>
<td>4</td>
</tr>
</tbody>
</table>

Table 5. Pre-morbid temperament/ traits/ personality.

<table>
<thead>
<tr>
<th>Personality trait</th>
<th>No. of cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well adjusted</td>
<td>64</td>
</tr>
<tr>
<td>Cluster ‘A’</td>
<td>3</td>
</tr>
<tr>
<td>Cluster ‘B’</td>
<td>8</td>
</tr>
<tr>
<td>Cluster ‘C’</td>
<td>12</td>
</tr>
<tr>
<td>Others</td>
<td>4</td>
</tr>
<tr>
<td>Not applicable</td>
<td>7</td>
</tr>
<tr>
<td>Low IQ</td>
<td>4</td>
</tr>
</tbody>
</table>

anxiety, depression and hostility (Table 6). Forty five percent fulfilled the ICD-10 criteria for a psychiatric disorder. The most common psychiatric diagnoses were mood (affective) disorders (23%) and anxiety neurosis (15%). Deliberate self harm was seen in 4%. Out of the total subjects, 55% had some clinically significant psychopathology which did not fulfill criteria for an ICD-10 diagnosis (Table 7). Migraine was the most common physical disease among these seizure cases (Table 8). The most common treatments included antiepileptic drugs. They required some sort of psycho-education, counseling or psychological intervention (Table 9).

DISCUSSION

Seizure disorder, including epilepsy, has the prevalence of about 1% of adult population (Hauser and Annegers, 1993) and is one of the most common and disabling
Table 6. Significant psychological symptoms of BPRS (with scores ≥ 4).

<table>
<thead>
<tr>
<th>BPRS item</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatic Concern</td>
<td>73</td>
</tr>
<tr>
<td>Anxiety</td>
<td>55</td>
</tr>
<tr>
<td>Emotional withdrawal</td>
<td>23</td>
</tr>
<tr>
<td>Concept disorganization</td>
<td>16</td>
</tr>
<tr>
<td>Guilt</td>
<td>8</td>
</tr>
<tr>
<td>Tension</td>
<td>39</td>
</tr>
<tr>
<td>Mannerism/posturing</td>
<td>69</td>
</tr>
<tr>
<td>Grandiosity</td>
<td>19</td>
</tr>
<tr>
<td>Depressed mood</td>
<td>42</td>
</tr>
<tr>
<td>Hostility</td>
<td>40</td>
</tr>
<tr>
<td>Suspiciousness</td>
<td>10</td>
</tr>
<tr>
<td>Hallucinatory behavior</td>
<td>56</td>
</tr>
<tr>
<td>Motor retardation</td>
<td>29</td>
</tr>
<tr>
<td>Uncooperativeness</td>
<td>23</td>
</tr>
<tr>
<td>Unusual thought content</td>
<td>8</td>
</tr>
<tr>
<td>Blunted affect</td>
<td>9</td>
</tr>
<tr>
<td>Excitement</td>
<td>37</td>
</tr>
<tr>
<td>Disorientation/derealize</td>
<td>89</td>
</tr>
</tbody>
</table>

Table 7. Psychiatric diagnosis#.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10 diagnosis present</td>
<td>45</td>
</tr>
<tr>
<td>Delirium</td>
<td>1</td>
</tr>
<tr>
<td>Substance use (F10-F19)</td>
<td>7</td>
</tr>
<tr>
<td>Schizophrenia (F20-29)</td>
<td>4</td>
</tr>
<tr>
<td>Mood (affective) (F30-39)</td>
<td>23</td>
</tr>
<tr>
<td>Neurotic, Stress, anxiety (F40-49)</td>
<td>15</td>
</tr>
<tr>
<td>Mental retardation</td>
<td>4</td>
</tr>
<tr>
<td>ADHD</td>
<td>1</td>
</tr>
<tr>
<td>Intentional self harm</td>
<td>4</td>
</tr>
<tr>
<td>Significant mental symptom only</td>
<td>55</td>
</tr>
</tbody>
</table>

Table 8. Co-morbid physical diagnosis#.

<table>
<thead>
<tr>
<th>Disease</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection/malignancy</td>
<td>3</td>
</tr>
<tr>
<td>Thyroid/endocrine</td>
<td>3</td>
</tr>
<tr>
<td>Migraine</td>
<td>12</td>
</tr>
<tr>
<td>Head injury</td>
<td>2</td>
</tr>
<tr>
<td>Cardio-vascular</td>
<td>3</td>
</tr>
<tr>
<td>Vertigo</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 9. Management strategies#.

<table>
<thead>
<tr>
<th>Treatment modality</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotic</td>
<td>15</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>23</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>18</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>49</td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>39</td>
</tr>
<tr>
<td>Other AED</td>
<td>26</td>
</tr>
<tr>
<td>Supplementation</td>
<td>25</td>
</tr>
<tr>
<td>Other/IV fluids</td>
<td>8</td>
</tr>
<tr>
<td>Counseling/psycho-education/psychological</td>
<td>78</td>
</tr>
</tbody>
</table>

Multiple response category: one respondent may have ≥ 1 responses.

neuro-psychiatric disorders (World Bank, 1993). It is basically the neuro-psychiatric manifestation of paroxysmal hyper-synchronous brain discharges (Mendez, 2009; Raghuthaman et al., 2005; Lishman, 1998). Different seizure or epilepsy types have various clinical features, for example alteration of consciousness (simple or complex) and convulsions (focal or generalized), as comprehensively classified by 'International League against Epilepsies' (1981) (Engel, 2001). Seizure is an important differential diagnosis in cases of episodic phenomena, with a mixture of neurological, somatic and psychiatric symptoms and seizure attack is sometimes precipitated by psycho-social stress, though to a less extent, as most of the mental disorders (Mendez, 2009; Raghuthaman et al., 2005).

Besides the psychiatric manifestations, seizure patients are reported to suffer more from various psychiatric problems than general population. Mood, anxiety and other neurotic (pseudo-seizures or dissociative), psychotic disorders, personality problems, mental retardation and cognitive changes, and suicide and self injurious behaviours are seen more among seizure cases (Mendez, 2009; Raghuthaman et al., 2005; Lishman, 1998). It is however, at times difficult to distinguish them as independent or secondary to seizure activity.

The co-morbid mental illness further worsens the quality of life of the patients. Hence, psychiatric manifestations and associations in seizures or epilepsies deserve a particular attention. Timely identification and proper management will enhance the better productivity and quality of life whereas seizure itself is reported under-diagnosed and under-treated (Eisenberg, 1997). More so because of prevalent myths and misconceptions about psychiatric illness, epileptics hesitate to seek help from mental health professionals even when they are in dire need.

There is a dearth of data about seizure, particularly about its psychiatric manifestations and associations in Nepalese context. We have to rely on our clinical...
Observations (Shakya, 2012) and to make assumptions from the data of other parts of world. This study aimed to explore the associated psychopathology and psychiatric co-morbidities in seizure disorders. It was also anticipated that it would open avenues for the studies in other aspects of the disease; like psycho-social, community based prevalence, etiological aspect etc.

This is a hospital based cross sectional descriptive study in 100 consecutive seizure disorder cases, with some psychiatric complaints or symptoms hence, coming in contact with the investigator in the Department of Psychiatry, BPKIHS, Dharan, Nepal during the study period. It utilized the ICD-10 and BPRS as research tools, both being administered by clinician and widely validated across the world (Overall and Gorham, 1962; Sajatovic and Ramirez, 2003). For pre-morbid personality problem, the cluster concept of Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV) (American Psychiatric Association, 2000) was adopted for the sake of simple and comprehensive categorization. As both systems of classification of disorders have similar or equivalent categories to a great extent, this cluster concept would not make much difference.

Majority of the subjects were in the age range of 10 to 39 years. It is on the whole because child and adolescent patients usually visit the Department of Pediatrics and adult patients visit Department of Psychiatry and Internal Medicine in this institute. The ‘male: female’ ratio being more or less 1:1 is consistent with most of the studies (Hauser and Annegers, 1993; Mendez, 2009; Raghuthaman et al., 2005). Mere 20% illiterate subjects seeking help in this study, obviously less than the general population, reflects the fact that more illiterate people might have been suffering from seizures or epilepsies in community without treatment (Eisenberg, 1997).

Most of the cases in this study were brought by family members when the symptoms did not disappear with other measures, mainly traditional healing, or when they developed additional problems like psychiatric illness. They presented late to medical services; less than one third of the subjects had come to this service within 1 year of the onset of seizure morbidity, reflecting the sad reality about the under-diagnosis (Eisenberg, 1997). Majority had sudden onset and episodic course of illness. Nearly half of the total subjects recall some precipitating stressors for seizure attacks, relational and health related problems being the most common ones.

When they presented to the health service, seizure related symptoms like loss or alteration of consciousness, misrecognition and abnormal body movements (stereotypy/mannerism) were the most common symptom items among the BPRS psychopathology. Other frequent psychopathologies were somatic concerns (headache, body ache, etc), hallucinatory behavior, anxiety, depression and hostility. Though in general population also, depression and anxiety are the most common mental problems (Murray and Lopez, 1996), they are even more among these epileptic subjects. This fact has been replicated in the diagnostic profile of this study too, showing mood and anxiety as being the most common psychiatric co-morbidity, and in the BPRS scoring of associated or manifested psychopathology, showing somatic concerns, hallucinatory behavior, anxiety, depression and hostility as being other most common symptom items with scores 4 or more. Thirty percent re-vealed to use psycho-active substances currently, mainly alcohol and nicotine, which was less than in other general psychiatry patients’ profile studies of this institute (Shakya et al., 2009), but clearly in excess to general population (Murray and Lopez, 1996).

One third of the subjects had some significant illness, mainly neuro-psychiatric illness in their past. More than two fifth (42%) of the subjects had family histories of significant illnesses. Fifteen percent of the subjects had some blood relatives with seizure which is similar to Western data (Mendez, 2009; Lishman, 1998).

In this hospital based study conducted in general psychiatry service setting, partial seizure (mainly complex) was the most common seizure type (49%), followed by generalized tonic clonic seizures (GTCS 43%). This is consistent with the fact about the prevalence of seizure types in adult population (Mendez, 2009; Raghuthaman et al., 2005). About one third had some personality traits significant enough to affect the clinical course of illness. People of all clusters were affected by seizures, though Cluster C traits were the most common. Mental retardation was present in 4 cases.

In seizure and epilepsy patients coming to this psychiatric service, 45% had psychiatric co-morbidities (ICD-10 diagnosis), mood and other neurotic/anxiety disorders being the most common as in Western/other studies (Mendez, 2009; Raghuthaman et al., 2005) and the remaining 55% had some significant mental symptoms, with the BPRS score 4 (moderate) or more but did not fulfill the ICD-10 criteria for any psychiatric disorder.

Suicide phenomena are relatively more in these seizure patients than in general population (Thapa and Carlough, 2000). The high rate may be because of the high co-morbidity and severe grading of psychopathology at the time of presentation. The suicide problem in this region needs validation with further community based studies.

As in other parts of the world, the Nepalese clinicians rely on various antiepileptic drugs like Carbamazepine, Sodium valproate and other anti-epileptic drugs. High psychiatric symptoms and co-morbidities were additional consideration during management of these cases; many of them needed benzodiazepines, anti-psychotics and antidepressants. Carbamazepine and Sodium valproate were over representing in this study, maybe because they were considered also for their mood stabilizing and other favorable effects besides antiepileptic property. Some
forms of psychological interventions are complimentary to drug therapy, for example psycho-education.

Our study is biased in a way since it enrolled only those patients who had some manifest mental symptoms and came in contact with the investigator in Department of Psychiatry. Hence, this may not reveal the true prevalence rate but we believe that this study satisfactorily depicts the range of possible psychopathology and psychiatric disorders associated with seizure disorders and looking at the cause and effect relationship of psychiatric symptom/disorder and seizure is beyond the objective/scope of current study which might be the topic for further research here. These observations however corroborate that psychiatric affliction, association, manifestation or co-morbidity is common in seizure disorders and epilepsies from different standpoints: etiological, clinical manifestations, co-morbidities and management. Hence, collaboration among various departments is crucial and it increases the success rate of treatment. The seizure patients should also be aware about these facts and should not hesitate to seek psychiatric help when needed.

Conclusions

1. Seizure and epilepsy patients usually present late (after 1 year of seizure) to the psychiatric service when they also have other co-morbidity, other traditional measures do not work, they are severely affected (high BPRS scores) and have to be brought by family members.
2. Some of them have past history of illness, including neuro-psychiatric illness. Many of them have family history of illness, including some with seizure disorder or epilepsy.
3. These seizure patients present with various symptoms such as altered consciousness, stereotypy, other somatic complaints, anxiety, hallucinatory behavior, mood symptoms, etc.
4. Some of them use substances, including alcohol and nicotine, and also have some significant personality traits, mainly of cluster ‘C’. A remarkable proportion of seizure patients presenting with some psychiatric symptoms fulfill the criteria for psychiatric disorders. Others with symptoms also have clinically significant ones. The most common psychiatric diagnosis was mood (affective) disorders, followed by neurotic, stress related and anxiety. A terrific number of them displayed deliberate self harm. Hence, seizure disorders have a wide range of psychiatric association as manifestation or co-morbidity.


REFERENCES

UPCOMING CONFERENCES


*International Conference on Cognitive and Behavioral Psychology, Italy, Venice, November 13-14, 2014*
Conferences and Advert

June 2013


November 2013

International Conference on Cognitive and Behavioral Psychology, Italy, Venice, November 13-14, 2014
Journal of Neuroscience and Behavioral Health

Related Journals Published by Academic Journals

- Journal of Diabetes and Endocrinology
- Journal of Medical Genetics and Genomics
- Journal of Public Health and Epidemiology
- Medical Case Studies
- Medical Practice and Reviews
- Journal of Infectious Diseases and Immunity